Biography:
Dr. Mark Feitelson received his Ph.D. in Microbiology and Immunology in 1979 from UCLA. He began his work with hepatitis B at Stanford University, and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). He has since worked on the pathogenesis of hepatitis B. In 1991, He moved to Thomas Jefferson University where he became Professor of Pathology and Cell Biology. He also was director of a Molecular Diagnostics Lab in Microbiology. In 2007, he went to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations, has more than 150 publications, and 180 abstracts. He is also CSO of SFA Therapeutics. He has 14 patents, has mentored over 130 students.